4//SEC Filing
TriVascular Technologies, Inc. 4
Accession 0001209191-16-095921
CIK 0001432732operating
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 2:04 PM ET
Size
21.2 KB
Accession
0001209191-16-095921
Insider Transaction Report
Form 4
DOUGLASS DAVID L
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
DELPHI VENTURES VII L P
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
DELPHI VENTURES VIII LP
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
DELPHI BIOINVESTMENTS VII LP
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
Delphi BioInvestments VIII LP
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
ROEDER DOUGLAS A
Director10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
BOCHNOWSKI JAMES J
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
PAKIANATHAN DEEPIKA
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
Transactions
- Disposition from Tender
Common Stock
2016-02-03−3,535,910→ 0 total(indirect: See Footnotes)
Footnotes (3)
- [F1]These shares were disposed of pursuant to the merger agreement between the Issuer and Endologix, Inc. ("Endologix") (such transaction, the "Merger"). In connection with the closing of the Merger, the Reporting Persons received 0.631 share of Endologix common stock and $0.34 in cash for each share of Issuer common stock held by such Reporting Persons, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016.
- [F2]These securities were directly held as follows: 1,464,553 shares by Delphi Ventures VII, L.P. ("Ventures VII"), 14,641 shares by Delphi BioInvestments VII, L.P. ("BioInvestments VII" and together with Ventures VII, the "Delphi VII Funds"), 2,036,831 shares by Delphi Ventures VIII, L.P. ("Ventures VIII") and 19,885 shares by Delphi BioInvestments VIII, L.P. ("BioInvestments VIII" and together with Ventures VIII, the "Delphi VIII Funds" and collectively with the Delphi VII Funds, the "Delphi Funds"). Delphi Management Partners VII, L.L.C. ("DMP VII") is the general partner of each of Ventures VII and BioInvestments VII and may be deemed to have sole voting and dispositive power over the securities held by the Delphi VII Funds. Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of each of Ventures VIII and BioInvestments VIII and may be deemed to have sole voting and dispositive power over the securities held by the Delphi VIII Funds.
- [F3]Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of each of DMP VII and DMP VIII and may be deemed to share voting and dispositive power over the securities held by the Delphi Funds. Such persons and entities disclaim beneficial ownership of the securities held by the Delphi Funds, except to the extent of any pecuniary interest therein.
Documents
Issuer
TriVascular Technologies, Inc.
CIK 0001432732
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001432732
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 2:04 PM ET
- Size
- 21.2 KB